Birinci Seçenek Anti-Tüberküloz İlaçlara Karşı Moleküler Direnç Mekanizmaları

World Health Organization (WHO). Global Tuberculosis Report, 2022. (01/02/2023 tarihinde https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 adresinden ulaşılmıştır ).

Grace, AG, Mittal A, Jain S, et al. (2019). Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis. Cochrane Database of Systematic Reviews, 2019;12: 1-79. doi.org/10.1002/14651858.CD012918.pub2.

Gopal P, Dick T. Reactive dirty fragments: implications for tuberculosis drug discovery. Curr Opin Microbiol. 2014;21: 7-12. doi: 10.1016/j.mib.2014.06.015.

Wolff KA, Nguyen L. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis. Expert Rev Anti Infect Ther. 2012;10(9): 971-81. doi: 10.1586/eri.12.87.

Khatun UF, Amin R, Islam, M, et al. Socio-demographic profile and drug sensitivity pattern of suspected drug resistant tuberculosis among patients in Regional Tuberculosis Reference Laboratory (RTRL) of a Tertiary Hospital. J Med. 2017;18(2): 62-7. doi: https://doi.org/10.3329/jom.v18i2.33680.

Perrin C, Athersuch K, Elder G, et al. Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study. BMJ Glob Health. 2022;7(4): e007490. doi: 10.1136/bmjgh-2021-007490.

Song L, Wu X. Development of efflux pump inhibitors in antituberculosis therapy. Int J Antimicrob Agents. 2016;47(6): 421-9. doi: 10.1016/j.ijantimicag.2016.04.007.

Subhash N, Sundaramurthy V. Advances in host-based screening for compounds with intracellular anti-mycobacterial activity. Cell Microbiol. 2021;23(7): e13337. doi: 10.1111/cmi.13337.

Fernandes GFDS, Salgado HRN, Santos JLD. Isoniazid: A Review of Characteristics, Properties and Analytical Methods. Crit Rev Anal Chem. 2017;47(4): 298-308. doi: 10.1080/10408347.2017.1281098.

Murray JF, Schraufnagel DE, Hopewell PC. Treatment of Tuberculosis. A Historical Perspective. Ann Am Thorac Soc. 2015;12(12): 1749-59. doi: 10.1513/AnnalsATS.201509-632PS.

World Health Organization (WHO). Global Tuberculosis Report, 2021. (03/02/2023 tarihinde https://reliefweb.int/report/world/global-tuberculosis-report-2021?gclid=EAIaIQobChMIguSbyoi4_QIVhdxRCh2isgMCEAAYASAAEgLI8vD_BwE adresinden ulaşılmıştır ).

Barozi V, Musyoka TM, Sheik Amamuddy O, et al. Deciphering Isoniazid Drug Resistance Mechanisms on Dimeric Mycobacterium tuberculosis KatG via Post-molecular Dynamics Analyses Including Combined Dynamic Residue Network Metrics. ACS Omega. 2022;7(15): 13313-32. doi: 10.1021/acsomega.2c01036.

Bodiguel J, Nagy JM, Brown KA, et al. Oxidation of isoniazid by manganese and Mycobacterium tuberculosis catalase-peroxidase yields a new mechanism of activation. J Am Chem Soc. 2001;123(16): 3832-3. doi: 10.1021/ja002674f.

Pierattelli R, Banci L, Eady NA, et al. Enzyme-catalyzed mechanism of isoniazid activation in class I and class III peroxidases. J Biol Chem. 2004;279(37): 39000-9. doi: 10.1074/jbc.M402384200.

Timmins GS, Master S, Rusnak F, et al. Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2004;48(8): 3006-9. doi: 10.1128/AAC.48.8.3006-3009.2004.

Peiró Cadahía J, Previtali V, Troelsen NS, et al. Prodrug strategies for targeted therapy triggered by reactive oxygen species. Medchemcomm. 2019;10(9): 1531-49. doi: 10.1039/c9md00169g.

Yan W, Zheng Y, Dou C, et al. The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development. Mol Biomed. 2022;3(1): 48. doi: 10.1186/s43556-022-00106-y.

Marrakchi H, Lanéelle G, Quémard AK. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology (Reading). 2000;146 ( Pt 2): 289-96. doi: 10.1099/00221287-146-2-289.

Rawat R, Whitty A, Tonge PJ. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc Natl Acad Sci USA. 2003;100(24): 13881-6. doi: 10.1073/pnas.2235848100.

Massengo-Tiassé RP, Cronan JE. Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009;66(9): 1507-17. doi: 10.1007/s00018-009-8704-7.

Zhu L, Bi H, Ma J, et al. The two functional enoyl-acyl carrier protein reductases of Enterococcus faecalis do not mediate triclosan resistance. mBio. 2013;4(5): e00613-13. doi: 10.1128/mBio.00613-13.

Vögeli B, Rosenthal RG, Stoffel GMM, et al. InhA, the enoyl-thioester reductase from Mycobacterium tuberculosis forms a covalent adduct during catalysis. J Biol Chem. 2018;293(44):17200-07. doi: 10.1074/jbc.RA118.005405.

Narmandakh E, Tumenbayar O, Borolzoi T, et al. Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia. Antimicrob Agents Chemother. 2020;64(7): e00537-20. doi: 10.1128/AAC.00537-20.

Rossini NO, Dias MVB. Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line. Genet Mol Biol. 2023;46(1 Suppl 2): e20220261. doi: 10.1590/1678-4685-GMB-2022-0261.

Bertrand T, Eady NA, Jones JN, Jesmin, et al. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J Biol Chem. 2004;279(37): 38991-9. doi: 10.1074/jbc.M402382200.

Zhao X, Yu H, Yu S, et al. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant. Biochemistry. 2006;45(13): 4131-40. doi: 10.1021/bi051967o.

Carpena X, Loprasert S, Mongkolsuk S, et al. Catalase-peroxidase KatG of Burkholderia pseudomallei at 1.7A resolution. J Mol Biol. 2003;327(2): 475-89. doi: 10.1016/s0022-2836(03)00122-0.

Vilchèze C, Wang F, Arai M, et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med. 2006;12(9): 1027-9. doi: 10.1038/nm1466.

Yu S, Girotto S, Lee C, et al. Reduced affinity for Isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance. J Biol Chem. 2003;278(17): 14769-75. doi: 10.1074/jbc.M300326200.

Ghiladi RA, Cabelli DE, Ortiz de Montellano PR. Superoxide reactivity of KatG: insights into isoniazid resistance pathways in TB. J Am Chem Soc. 2004;126(15): 4772-3. doi: 10.1021/ja031728t.

Musser JM, Kapur V, Williams DL, et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis. 1996;173(1):196-202. doi: 10.1093/infdis/173.1.196.

Wei CJ, Lei B, Musser JM, et al. Isoniazid activation defects in recombinant Mycobacterium tuberculosis catalase-peroxidase (KatG) mutants evident in InhA inhibitor production. Antimicrob Agents Chemother. 2003;47(2): 670-5. doi: 10.1128/AAC.47.2.670-675.2003.

Thwe EP, Namwat W, Pinlaor P, et al. Novel mutations detected from drug resistant Mycobacterium tuberculosis isolated from North East of Thailand. World J Microbiol Biotechnol. 2021;37(11): 194. doi: 10.1007/s11274-021-03163-7.

Kandler JL, Mercante AD, Dalton TL, et al. Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests. Antimicrob Agents Chemother. 2018;62(10): e00974-18. doi: 10.1128/AAC.00974-18.

Islam MM, Tan Y, Hameed HMA, et al. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. Clin Microbiol Infect. 2019;25(8):1041.e1-1041.e7. doi: 10.1016/j.cmi.2018.12.008.

Wang L, Yang J, Chen L, et al. Whole-genome sequencing of Mycobacterium tuberculosis for prediction of drug resistance. Epidemiol Infect. 2022;150:e22. doi: 10.1017/S095026882100279X.

Musser JM, Kapur V, Williams DL, et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis. 1996;173(1): 196-202. doi: 10.1093/infdis/173.1.196.

Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79(1): 3-29. doi: 10.1054/tuld.1998.0002.

Seifert M, Catanzaro D, Catanzaro A, et al. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015;10(3): e0119628. doi: 10.1371/journal.pone.0119628.

Vilchèze C, Jacobs WR Jr. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Microbiol Spectr. 2014;2(4): MGM2-0014-2013. doi: 10.1128/microbiolspec.MGM2-0014-2013.

Oliveira JS, Pereira JH, Canduri F, et al. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis. J Mol Biol. 2006;359(3): 646-66. doi: 10.1016/j.jmb.2006.03.055.

Dias MV, Vasconcelos IB, Prado AM, et al. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. J Struct Biol. 2007;159(3):369-80. doi: 10.1016/j.jsb.2007.04.009.

Basso LA, Zheng R, Musser JM, et al. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis. 1998;178(3): 769-75. doi: 10.1086/515362.

Brucoli F, D McHugh T. Rifamycins: do not throw the baby out with the bathwater. Is rifampicin still an effective anti-tuberculosis drug? Future Med Chem. 2021;13(24): 2129-31. doi: 10.4155/fmc-2021-0249.

Zloh M, Gupta M, Parish T, et al. Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoBS522L strain and display a different binding mode at the RNAP β-subunit site compared to rifampicin. Eur J Med Chem. 2021;225: 113734. doi: 10.1016/j.ejmech.2021.

Grobbelaar M, Louw GE, Sampson SL, et al. Evolution of rifampicin treatment for tuberculosis. Infect Genet Evol. 2019;74:103937. doi: 10.1016/j.meegid.2019.103937.

Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001;104(6): 901-12. doi: 10.1016/s0092-8674(01)00286-0.

Betts JC, Lukey PT, Robb LC, et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol. 2002 Feb;43(3):717-31. doi: 10.1046/j.1365-2958.2002.02779.x.

Goldstein BP. Resistance to rifampicin: a review. J Antibiot (Tokyo). 2014;67(9): 625-30. doi: 10.1038/ja.2014.107.

Pang Y, Lu J, Wang Y, et al. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57(2): 893-900. doi: 10.1128/AAC.01024-12.

Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2001;2(3):164-8. doi: 10.1186/rr54.

McNerney R, Kiepiela P, Bishop KS, et al. Rapid screening of Mycobacterium tuberculosis for susceptibility to rifampicin and streptomycin. Int J Tuberc Lung Dis. 2000 Jan;4(1): 69-75.

Mikhailovich V, Lapa S, Gryadunov D, et al. Identification of rifampin-resistant Mycobacterium tuberculosis strains by hybridization, PCR, and ligase detection reaction on oligonucleotide microchips. J Clin Microbiol. 2001;39(7): 2531-40. doi: 10.1128/JCM.39.7.2531-2540.2001.

Hirani N, Joshi A, Anand S, et al. Detection of a novel mutation in the rpoB gene in a multidrug resistant Mycobacterium tuberculosis isolate using whole genome next generation sequencing. J Glob Antimicrob Resist. 2020 Sep;22:270-274. doi: 10.1016/j.jgar.2020.03.004.

Sinha P, Srivastava GN, Tripathi R, et al. Detection of mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains inhibiting wild type probe hybridization in the MTBDR plus assay by DNA sequencing directly from clinical specimens. BMC Microbiol. 2020;20(1): 284. doi: 10.1186/s12866-020-01967-5.

Takawira FT, Mandishora RSD, Dhlamini Z, et al. Mutations in rpoB and katG genes of multidrug resistant mycobacterium tuberculosis undetectable using genotyping diagnostic methods. Pan Afr Med J. 2017;27:145. doi: 10.11604/pamj.2017.27.145.10883.

Maningi NE, Daum LT, Rodriguez JD, et al. Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a Molecular Analysis of Historical Isolates. J Clin Microbiol. 2018;56(5): e01214-17. doi: 10.1128/JCM.01214-17.

Machado D, Coelho TS, Perdigão J, et al. Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis. Front Microbiol. 2017;8: 711. doi: 10.3389/fmicb.2017.00711.

Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health. 2014;7(2):75-91. doi: 10.1016/j.jiph.2013.09.001.

Miotto P, Cabibbe AM, Borroni E, et al. Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis. J Clin Microbiol. 2018;56(5): e01599-17. doi: 10.1128/JCM.01599-17.

Al-Mutairi NM, Ahmad S, Mokaddas E, et al. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. BMC Infect Dis. 2019;19(1): 3. doi: 10.1186/s12879-018-3638-z.

Al-Mutairi NM, Ahmad S, Mokaddas EM. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB. Eur J Med Res. 2019;24(1): 38. doi: 10.1186/s40001-019-0397-2.

Shea J, Halse TA, Kohlerschmidt D, et al. Low-Level Rifampin Resistance and rpoB Mutations in Mycobacterium tuberculosis: an Analysis of Whole-Genome Sequencing and Drug Susceptibility Test Data in New York. J Clin Microbiol. 2021;59(4): e01885-20. doi: 10.1128/JCM.01885-20.

Ma P, Luo T, Ge L, et al. Compensatory effects of M. tuberculosis rpoB mutations outside the rifampicin resistance-determining region. Emerg Microbes Infect. 2021;10(1): 743-52. doi: 10.1080/22221751.2021.1908096.

Nusrath Unissa A, Hanna LE, Swaminathan S. A Note on Derivatives of Isoniazid, Rifampicin, and Pyrazinamide Showing Activity Against Resistant Mycobacterium tuberculosis. Chem Biol Drug Des. 2016;87(4): 537-50. doi: 10.1111/cbdd.12684.

Nusrath Unissa A, Hanna LE. Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era. Tuberculosis (Edinb). 2017;105: 96-107. doi: 10.1016/j.tube.2017.04.008.

Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis. 2003;7(1): 6-21.

Njire M, Tan Y, Mugweru J, et al. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Adv Med Sci. 2016;61(1): 63-71. doi: 10.1016/j.advms.2015.09.007.

Hu Y, Coates AR, Mitchison DA. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2006;10(3): 317-22.

Zhang Y, Shi W, Zhang W, et al. Mechanisms of Pyrazinamide Action and Resistance. Microbiol Spectr. 2014;2(4): MGM2-0023-2013. doi: 10.1128/microbiolspec.

Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science. 2011;333(6049): 1630-2. doi: 10.1126/science.1208813.

Sun Q, Li X, Perez LM, et al. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nat Commun. 2020;11(1): 339. doi: 10.1038/s41467-019-14238-3.

Feuerriegel S, Köser CU, Richter E, et al. Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid. J Antimicrob Chemother. 2013;68(6):1439-40. doi: 10.1093/jac/dkt042.

Özgür D, Tezcan Ülger S, Kayar MB, et al. Investigation of pncA, rpsA and panD gene mutations associated with resistance in pyrazinamide-resistant mycobacterium tuberculosis isolates and spoligotyping. Mikrobiyol Bul. 2022 ;56(2): 191-205. doi: 10.5578/mb.20229801.

Hameed HA, Tan Y, Islam MM, et al. Detection of Novel Gene Mutations Associated with Pyrazinamide Resistance in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Southern China. Infect Drug Resist. 2020;13:217-227. doi: 10.2147/IDR.S230774.

Zhang S, Chen J, Shi W, et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect. 2013;2(6): e34. doi: 10.1038/emi.2013.38.

Daum LT, Konstantynovska OS, Solodiankin OS, et al. Characterization of novel Mycobacterium tuberculosis pncA gene mutations in clinical isolates from the Ukraine. Diagn Microbiol Infect Dis. 2019;93(4): 334-38. doi: 10.1016/j.diagmicrobio.2018.10.018.

Khan MT, Junaid M, Mao X, et al. Pyrazinamide resistance and mutations L19R, R140H, and E144K in Pyrazinamidase of Mycobacterium tuberculosis. J Cell Biochem. 2019;120(5): 7154-66. doi: 10.1002/jcb.27989.

Li K, Yang Z, Gu J, et al. Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, China. Front Microbiol. 2021;11: 594171. doi: 10.3389/fmicb.2020.594171.

Tan YZ, Rodrigues J, Keener JE, et al. Cryo-EM structure of arabinosyltransferase EmbB from Mycobacterium smegmatis. Nat Commun. 2020;11(1): 3396. doi: 10.1038/s41467-020-17202-8.

Zhang L, Zhao Y, Gao Y, et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science. 2020;368(6496): 1211-19. doi: 10.1126/science.aba9102.

Bendre AD, Peters PJ, Kumar J. Recent Insights into the Structure and Function of Mycobacterial Membrane Proteins Facilitated by Cryo-EM. J Membr Biol. 2021;254(3): 321-41. doi: 10.1007/s00232-021-00179-w.

Goude R, Amin AG, Chatterjee D, et al. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009;53(10): 4138-46. doi: 10.1128/AAC.00162-09.

Wolucka BA, McNeil MR, de Hoffmann E, et al. Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem. 1994;269(37): 23328-35.

Zhu C, Liu Y, Hu L, et al. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis. J Biol Chem. 2018;293(43): 16741-50. doi: 10.1074/jbc.RA118.002693.

Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis. 2015;19(11): 1276-89. doi: 10.5588/ijtld.15.0389.

Cui Z, Li Y, Cheng S, et al. Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol. Antimicrob Agents Chemother. 2014;58(11): 6837-43. doi: 10.1128/AAC.03285-14.

Safi H, Sayers B, Hazbón MH, et al. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother. 2008;52(6): 2027-34. doi: 10.1128/AAC.01486-07.

Plinke C, Cox HS, Zarkua N, et al. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation. J Antimicrob Chemother. 2010;65(7): 1359-67. doi: 10.1093/jac/dkq120.

Dai E, Zhang H, Zhou X, et al. MycoResistance: a curated resource of drug resistance molecules in Mycobacteria. Database (Oxford). 2019;2019: baz074. doi: 10.1093/database/baz074.

Plinke C, Cox HS, Kalon S, et al. Tuberculosis ethambutol resistance: concordance between phenotypic and genotypic test results. Tuberculosis (Edinb). 2009;89(6): 448-52. doi: 10.1016/j.tube.2009.09.001.

Li D, Song Y, Zhang CL, et al. Screening mutations in drug-resistant Mycobacterium tuberculosis strains in Yunnan, China. J Infect Public Health. 2017;10(5): 630-36. doi: 10.1016/j.jiph.2017.04.008.

Park J, Jang W, Kim M, et al. Molecular drug resistance profiles of Mycobacterium tuberculosis from sputum specimens using ion semiconductor sequencing. J Microbiol Methods. 2018;145: 1-6. doi: 10.1016/j.mimet.2017.12.003.

Park J, Shin SY, Kim K, et al. Determining Genotypic Drug Resistance by Ion Semiconductor Sequencing With the Ion AmpliSeq™ TB Panel in Multidrug-Resistant Mycobacterium tuberculosis Isolates. Ann Lab Med. 2018;38(4): 316-23. doi: 10.3343/alm.2018.38.4.316.

Sun Q, Xiao TY, Liu HC, et al. Mutations within embCAB Are Associated with Variable Level of Ethambutol Resistance in Mycobacterium tuberculosis Isolates from China. Antimicrob Agents Chemother. 2017;62(1): e01279-17. doi: 10.1128/AAC.01279-17.